UTAH MEDICAL PRODUCTS INC Form 10-Q May 11, 2009

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q

Quarterly Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934

For quarter ended: March Commission File No.

31, 2009 0-11178

UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter)

UTAH 87-0342734 (State or other jurisdiction (I.R.S. Employer

of

incorporation or organization)

Identification No.)

7043 South 300 West Midvale, Utah 84047 Address of principal executive offices

Registrant's telephone number: (801) 566-1200

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and; (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer o Accelerated filer x Non-accelerated filer o Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x

Indicate the number of shares outstanding of each of the issuer's classes of common stock as of May 8, 2009: 3,603,000.

UTAH MEDICAL PRODUCTS, INC. INDEX TO FORM 10-Q

PART I - FINANCIAL INFORMATION			
Item 1.	Financial Statements		
	Consolidated Condensed Balance Sheets as of March 31, 2009 and December 31, 2008	1	
	Consolidated Condensed Statements of Income for the three months ended March 31, 2009 and March 31, 2008	0 2	
	Consolidated Condensed Statements of Cash Flows for three months ended March 31, 2009 and March 31, 2008) 3	
	Notes to Consolidated Condensed Financial Statements	4	
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	7	
Item 3.	Quantitative and Qualitative Disclosures about Market Risk		
Item 4.	Controls and Procedures	11	
PART II – OTHER I	NFORMATION		
Item 1A.	Risk Factors	12	
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	12	
Item 6.	Exhibits	12	
SIGNATURES		12	

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES CONSOLIDATED CONDENSED BALANCE SHEETS AS OF MARCH 31, 2009 AND DECEMBER 31, 2008

(in thousands)

ASSETS	(unaudited) MARCH 31, 2009		(audited) DECEMBER 31, 2008	
Current assets:				
Cash	\$	855	\$	97
Investments, available-for-sale		17,205		15,927
Accounts & other receivables -				
net		3,200		3,517
Inventories		3,703		3,275
Other current assets		600		463
Total current assets		25,564		23,280
Property and equipment - net		7,811		8,127
Goodwill		7,191		7,191
Other intangible assets		2,656		2,653
Other intangible assets -				
accumulated amortization		(2,438)		(2,430)
Other intangible assets - net		217		223
TOTAL	\$	40,783	\$	38,821
LIABILITIES AND				
STOCKHOLDERS' EQUITY				
Current liabilities:				
Accounts payable	\$	600	\$	418
Accrued expenses		2,636		1,086
Current portion of note payable		242		265
Total current liabilities		3,478		1,768
Note payable		1,509		1,828
Deferred income taxes		405		420
Total liabilities		5,391		4,016

Stockholders' equity:

Preferred stock - \$.01 par value;

authorized - 5,000

shares; no shares issued or outstanding
Common stock - \$.01 par value;
authorized - 50,000
shares; issued - March 31,
2009, 3,608 shares and
December 31, 2008, 3,603
shares
Accumulated other
comprehensive income (1

shares	36	36
Accumulated other		
comprehensive income	(1,357)	(1,122)
Retained earnings	36,713	35,892
Total stockholders' equity	35,392	34,805
TOTAL	\$ 40,783	\$ 38,821
see notes to consolidated		

see notes to consolidated condensed financial statements

- 1 -

UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE THREE MONTHS ENDED MARCH 31, 2009 AND MARCH 31, 2008 (in thousands, except per share amounts) (unaudited)

THREE MONTHS ENDED

	MARCH 31,		
	2009		2008
Sales, net	\$ 6,445	\$	6,890
Cost of goods sold	2,945		3,139
Gross profit	3,500		3,750
Operating expense			
Selling, general and administrative	952		1,118
Research & development	89		92
Total	1,041		1,210
Operating income	2,459		2,540
Other income	9		203
Income before provision for income taxes	2,468		2,743
Provision for income taxes	876		852
Net income	\$ 1,592	\$	1,891
Earnings per common share (basic)	\$ 0.44	\$	0.49
Earnings per common share (diluted)	\$ 0.44	\$	0.48
Shares outstanding - basic	3,606		3,887
Shares outstanding - diluted	3,619		3,930
see notes to consolidated condensed financial statements			

UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED MARCH 31, 2009 AND MARCH 31, 2008

(in thousands - unaudited)

		MARCH 31	
	2009		2008
CASH FLOWS FROM			
OPERATING ACTIVITIES:	.	700	A 1001
Net income	\$ 1,	592	\$ 1,891
Adjustments to reconcile net			
income to net			
cash provided by operating			
activities:		1.40	1.47
Depreciation and amortization		143	147
Gain on investments		(47)	(128)
Provision for losses on accounts		(-)	(4.0)
receivable		(5)	(10)
Loss on disposal of assets		-	0
Deferred income taxes		-	(77)
Stock-based compensation			
expense		31	31
Changes in operating assets and			
liabilities:			
Accounts receivable - trade		293	97
Accrued interest and other		_	
receivables		3	(200)
Inventories	(-	449)	(457)
Prepaid expenses and other current			
assets	·	113)	(92)
Accounts payable		182	92
Accrued expenses		726	446
Total adjustments	,	765	(151)
Net cash provided by operating			
activities	2,	357	1,740
CASH FLOWS FROM			
INVESTING ACTIVITIES:			
Capital expenditures for:			
Property and equipment		(83)	(85)
Intangible assets		(3)	(4)
Purchases of investments	(1,	300)	(1,000)
Proceeds from sale of investments		-	921
Net cash used in investing			
activities	(1,	386)	(168)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from issuance of		
common stock - options	25	133
Common stock purchased and		
retired	-	(921)
Tax benefit attributable to exercise		
of stock options	3	36
Repayments of note payable	(231)	(251)
Payment of dividends	-	